SCHEMBL2998196

SCHEMBL2998196

Cc1ccccc1Cc1csc(N2CCC(S(=O)(=O)c3cc(C(F)(F)F)ccc3Cl)CC2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TSHR P16473 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
RAB9A P51151 1/20 0.38
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
EPHX2 P34913 1/20 0.36
MCL1 Q07820 1/20 0.36
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
POLB P06746 2/20 0.34
CTSS P25774 1/20 0.34
MAPK1 P28482 1/20 0.34
SCD O00767 1/20 0.33
CA2 P00918 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ADRB2 P07550 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014184 0.90 RECQL (0.38) MEN1KMT2AALDH1A1TSHRL3MBTL1
SCHEMBL2999638 0.90 TSHR (0.37) MEN1KMT2AALDH1A1TSHRATM
SCHEMBL3007165 0.89 RAB9A (0.49) MEN1KMT2AALDH1A1TSHRATM
SCHEMBL3003881 0.88 MEN1 (0.41) MEN1KMT2AALDH1A1TSHRATM
SCHEMBL3015436 0.88 EPHX2 (0.40) MEN1KMT2AALDH1A1TSHRATM
SCHEMBL3010356 0.87 CTSS (0.42) MEN1KMT2ARAB9ALMNASMN1; SMN2
SCHEMBL3012889 0.87 ALDH1A1 (0.39) MEN1KMT2AALDH1A1TSHRATM
SCHEMBL3010474 0.86 MEN1 (0.41) MEN1KMT2AALDH1A1TSHRATM
SCHEMBL3008914 0.86 LMNA (0.38) MEN1KMT2ARAB9ALMNAEPHX2
SCHEMBL3009061 0.86 KMT2A (0.38) MEN1KMT2AALDH1A1TSHRATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885KMT2A 2680/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.